Scinai Immunotherapeutics Ltd. — filing summary
Entity and period: The supplied filing is BiondVax Pharmaceuticals Ltd.’s annual Form 20-F for the fiscal year ended December 31, 2021, filed March 28, 2022—not a Scinai Immunotherapeutics filing or a quarterly report. The filing reports under IFRS, as issued by the IASB. No standalone Q4 results are provided.
Business context
BiondVax had no product revenue and was a development-stage biopharmaceutical company. Its M-001 universal influenza vaccine failed to meet primary and secondary efficacy endpoints in a Phase 3 trial announced in 2020; development was discontinued. The company shifted toward a diversified pipeline, beginning with nanosized antibodies (NanoAbs). In December 2021, it signed collaboration and licensing agreements with the Max Planck Society (MPG) and University Medical Center Göttingen (UMG) for COVID-19 NanoAbs, effective January 1, 2022. At year-end, it had no product candidates in clinical trials or approved for sale.
Financial results and liquidity
- Revenue: None reported; the company had generated no revenue since inception. Revenue margins are therefore not applicable.
- Net loss: $12.9 million in 2021, versus $1.4 million in 2020 and $31.6 million in 2019. The unusually low 2020 loss reflected substantial other income, including revaluation of EIB financing and grant liabilities; it is not indicative of recurring operating performance.
- Operating costs: R&D expense, net, fell to $3.3 million from $16.5 million in 2020, mainly following the M-001 Phase 3 failure. Marketing, general and administrative expense rose to $7.9 million from $5.4 million, including higher compensation, professional services and insurance costs.
- Cash flow: Operating activities used $7.9 million in 2021, compared with $23.3 million in 2020. Investing activities used $0.1 million; financing activities provided $21.8 million, mainly from equity offerings.
- Cash and liquidity: Cash and cash equivalents were $17.4 million at December 31, 2021, compared with $3.0 million a year earlier. Working capital was $15.4 million. Management’s runway statements differ: the financial-statement note says resources were sufficient for at least 12 months, while MD&A estimates at least 24 months at then-current monthly rates.
- Debt: The EIB facility totaled €24 million. At year-end, its carrying value was $20.3 million, while the filing gives nominal principal of $27.2 million. The loan was secured by a first-ranking floating charge over substantially all company assets, subject to stated exclusions. Lease liabilities were approximately $2.1 million.
- Equity and dilution: The company raised gross proceeds of approximately $13.8 million in February 2021 and $9.8 million in December 2021. The filing’s cover reports 573.3 million ordinary shares outstanding at period-end, while the audited balance sheet reports 739.0 million issued and outstanding at December 31, 2021; these figures are inconsistent and should be checked.
Changes, outlook and material risks
- The company’s strategic pivot followed M-001’s Phase 3 failure. Its new NanoAbs work was early-stage, with cited COVID-19 variant activity based on in-vitro studies and, for Omicron, in-silico analysis—not clinical evidence.
- The filing describes continued expected losses and negative operating cash flow, with additional financing likely needed to advance development. Financing may dilute shareholders or require restrictive terms or concessions.
- After year-end, the company announced a commercial agreement with EIB to restructure the loan, subject to EIB formal approval and definitive documentation. Proposed terms included extending maturities to December 2027, 7% annual interest accruing from January 1, 2022, a $0.9 million principal payment, and use of 10% of future capital raises for further repayment. The filing cautions that completion was not assured.
- Other significant risks include EIB acceleration and enforcement against collateral; dependence on MPG/UMG and license terms; scientific, clinical, regulatory, manufacturing and commercialization uncertainty; COVID-19 variant evolution and changing demand; competition; and the need for additional capital. The company also disclosed foreign-exchange exposure, principally to the U.S. dollar and euro.
- The auditor issued an unmodified opinion. Its critical audit matter concerned impairment assessment of factory leasehold assets, which had a net carrying value of NIS 38.0 million. Management recognized no impairment; the estimate depended on assumptions about alternative-use cash flows and discount rates.
- Management reported that disclosure controls and internal control over financial reporting were effective at December 31, 2021, and said previously reported material weaknesses had been remediated during the year.
Important facts for investors to verify
- Confirm the issuer and reporting period: the document is BiondVax’s FY2021 Form 20-F, not Scinai’s filing or a Q4-only report.
- Reconcile the conflicting year-end share counts (573.3 million on the cover versus 739.0 million in the audited balance sheet) and assess subsequent dilution.
- Check the finalized EIB restructuring documents, loan principal, interest, maturity, security and any default or covenant status; distinguish carrying value from nominal principal.
- Reconcile the conflicting cash-runway estimates of at least 12 versus 24 months and monitor actual cash burn and financing needs.
- Verify the status, milestones, costs and rights under the MPG/UMG agreements, and whether any NanoAb candidates advance beyond preclinical evidence.
- Review the basis for the factory asset valuation and the assumptions supporting the no-impairment conclusion.